Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) Director Sells $304,220.35 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Director Simon Read sold 2,777 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $109.55, for a total value of $304,220.35. Following the completion of the sale, the director directly owned 2,777 shares of the company’s stock, valued at $304,220.35. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH opened at $109.60 on Friday. Dianthus Therapeutics, Inc. has a 52-week low of $19.84 and a 52-week high of $114.55. The business’s 50 day simple moving average is $96.76 and its two-hundred day simple moving average is $82.61. The firm has a market cap of $5.99 billion, a P/E ratio of -26.41 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The firm had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. On average, equities analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on DNTH shares. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. HC Wainwright boosted their target price on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Truist Financial upped their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $124.27.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DNTH. First Horizon Corp purchased a new position in Dianthus Therapeutics during the first quarter worth about $32,000. Global Retirement Partners LLC purchased a new stake in Dianthus Therapeutics in the 2nd quarter valued at about $93,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Dianthus Therapeutics during the 4th quarter worth approximately $40,000. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $27,000. Finally, Russell Investments Group Ltd. purchased a new position in shares of Dianthus Therapeutics in the 3rd quarter worth approximately $64,000. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.